Nykode Therapeutics ASA (OSE:NYKD), a clinical-stage biopharmaceutical company, announced on Thursday an expanded clinical collaboration and supply agreement with Swiss healthcare company Roche (SIX:ROG) to evaluate its cancer vaccine candidate, VB10.16, in combination with Roche's cancer immunotherapy atezolizumab (Tecentriq) in patients with advanced cervical cancer.
The VB-C-04 trial, expected to start in the fourth quarter of 2023 in the US, provides a potential fast-to-market path. Under the agreement Nykode will sponsor and fund the trial, while Roche will supply atezolizumab. Nykode retains global commercial rights to VB10.16.
Positive results from the Phase 2 VB-C-02 trial in Europe demonstrated an overall response rate (ORR) of 29%, median overall survival (mOS) greater than 25 months, and 6.3 months median progression-free survival (mPFS) in PD-L1+ patients. In the patient population relevant to the upcoming VB-C-04 trial, ORR was 40%, disease control rate was 80%, and mPFS was 16.9 months.
VB10.16, based on Nykode's Vaccibody technology platform, is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate designed to target antigens to antigen-presenting cells.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic